A randomised, double-blind, placebo-controlled trial of oral propranolol for hereditary haemorrhagic telangiectasia
Background: Early evidence suggests beta-blockers may have a disease-modifying effect in hereditary haemorrhagic telangiectasia (HHT). We aimed to assess the efficacy of oral propranolol is reducing severity of HHT-related epistaxis. Methods: A randomised, double blind, placebo controlled clinical trial was conducted in adults with HHT experiencing epistaxis. Subjects were randomly assigned to rec
